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Abstract
Background: Identification of targetable EML4-ALK fusion proteins has revolutionized the treatment of a minor
subgroup of non-small cell lung cancer (NSCLC) patients. Although fluorescence in situ hybridization (FISH) is
regarded as the gold standard for detection of ALK rearrangements, ALK immunohistochemistry (IHC) is often
used as screening tool in clinical practice. In order to unbiasedly analyze the diagnostic impact of such a screening
strategy, we compared ALK IHC with ALK FISH in three large representative Swedish NSCLC cohorts incorporating
clinical parameters and gene expression data.
Methods: ALK rearrangements were detected using FISH on tissue microarrays (TMAs), including tissue from 851
NSCLC patients. In parallel, ALK protein expression was detected using IHC, applying the antibody clone D5F3
with two different protocols (the FDA approved Ventana CDx assay and our in house Dako IHC protocol). Gene
expression microarray data (Affymetrix) was available for 194 patients.
Results: ALK rearrangements were detected in 1.7 % in the complete cohort and 2.0 % in the non-squamous cell
carcinoma subgroup. ALK protein expression was observed in 1.8 and 1.4 % when applying the Ventana assay or
the in house Dako protocol, respectively. The specificity and accuracy of IHC was high (> 98 %), while the sensitivity
was between 69 % (Ventana) and 62 % (in house Dako protocol). Furthermore, only 67 % of the ALK IHC positive cases
were positive with both IHC assays. Gene expression analysis revealed that 6/194 (3 %) tumors showed high ALK gene
expression (≥ 6 AU) and of them only three were positive by either FISH or IHC.
Conclusion: The overall frequency of ALK rearrangements based on FISH was lower than previously reported. The
sensitivity of both IHC assays was low, and the concordance between the FISH and the IHC assays poor, questioning
current strategies to screen with IHC prior to FISH or completely replace FISH by IHC.
Background
Lung cancer is the leading cause of death due to cancer
worldwide [1]. The disease comprises histologically dif-
ferent entities where non-small cell lung cancer
(NSCLC) presents the majority [2]. The prognosis is
poor, with a five-year survival rate of approximately
15 % across all stages [3]. In recent years, comprehensive
molecular studies have identified genomic aberrations
leading to activating mutations in cancer drivers, proto-
typically presented by EGFR mutation, found in 10–50 %
of adenocarcinoma patients [4, 5]. Subsequently, another
cancer driver was discovered, a gene rearrangement on
chromosome 2, leading to the fusion gene between ech-
inoderm microtubule associated protein like 4 (EML4)
and anaplastic lymphoma kinase (ALK) [6, 7]. This aber-
ration is present in 3–13 % of NSCLC patients [6, 8–10].
ALK is a receptor tyrosine kinase belonging to the
insulin growth factor receptor superfamily [11]. The
specific physiological function of ALK is not yet clari-
fied. However, ALK is believed to play a role in the
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development of the nervous system [12]. ALK deficient
mice showed only mild behavioral phenotypes, propos-
ing that ALK is not essential for viability [13–15]. In
lung cancer, the fusion of ALK with EML4 leads to con-
stitutive activation of ALK, directly affecting down-
stream signaling and increasing cell proliferation and
survival [6]. Since the discovery of the EML4-ALK
fusion in 2007, several other ALK fusion partners have
been described, such as kinesin family member 5B
(KIF5B) [16], kinesin light chain 1 (KLC1) [17] and
TRK-fused gene (TFG) [7], all fusion products leading
to comparable kinase activation and transforming cap-
acities [9, 18].
Soon after the discovery of ALK translocations in lung
cancer, patients harboring this fusion gene demonstrated
impressive response rates in clinical trials when treated
with the ALK inhibitor crizotinib [19, 20]. The results of
a subsequent phase III trial led to an accelerated
approval from the United States Food and Drug Admin-
istration (FDA) of crizotinib as first-line therapy in ALK
positive advanced NSCLC patients [21]. Two ALK
inhibitors have been approved [22] and several are in
late clinical trials [23], but the identification of the
small patient subset that harbors the ALK rearrange-
ment remains a diagnostic challenge.
As for many other chromosomal aberrations, fluores-
cence in situ hybridization (FISH) is the gold standard
for the detection of ALK rearrangement [24]. The use
of ALK inhibitors was, until recently, based on a posi-
tive FISH assay [25], although it is difficult to detect
the small inversion on chromosome 2 by a fluorescence
probe. Split signals can be narrow and the analysis of
small biopsies, with tissue artefacts and limited amounts
of cancer cells, aggravates the problem [26]. Moreover, as
FISH analysis is time consuming and relatively expensive,
laboratories have tried to introduce other assays to identify
the rearrangement. Based on the observation that the
ALK fusion gene results in a highly expressed fusion pro-
tein [6, 7], several immunohistochemical (IHC) assays
have been established for primary screening of clinical
samples, with subsequent confirmation of positive cases
by FISH [24, 27–29]. The approach described above has
also been discussed in several national diagnostic
guidelines [30–32]. However, in 2015 the FDA ap-
proved an IHC assay (Ventana ALK (D5F3) CDx Assay,
Roche Diagnostics Limited, UK) that aims to completely
replace FISH for detection of ALK rearrangements. Evi-
dently, both protein and genomic levels provide informa-
tion to guide patient therapy, and it is surprising that gene
expression, representing the molecular link between DNA
and protein alterations, only rarely has been included for
the assessment of ALK rearrangements.
The aim of this study was to evaluate the relation be-
tween ALK rearrangement, protein expression and gene
expression in three large representative Swedish NSCLC
cohorts. We compared FISH analysis with two IHC as-
says in 851 clinically annotated NSCLC cases. The first
IHC protocol was the recently FDA approved Ventana
CDx assay with the ALK clone D5F3 [33]. The second
protocol applied was an in house protocol using the
same antibody clone on a Dako Autostainer. The results
were supplemented with gene expression data obtained
from an Affymetrix microarray study.
Methods
Patient cohorts and clinical characteristics
The study population consisted of 851 radically resected
NSCLC patients, distributed over three patient cohorts.
The first cohort (Uppsala I) included 354 patients op-
erated 1995–2005. Frozen tissue was available for 194
patients and from these RNA was isolated and utilized
for gene expression analysis, as previously described
[34, 35]. Corresponding formalin-fixed paraffin-embedded
(FFPE) tissue blocks were available for 188 of the 194
patients and these were included in a tissue microarray
(TMA), together with 166 additional samples (n = 354), as
previously described [36, 37].
The second cohort (Uppsala II) included 354 patients
operated 2006–2010 [38, 39]. FFPE material was avail-
able from all patients, and tissue cores from each tumor
block were incorporated in a TMA.
The Örebro cohort consisted of 262 patients surgically
resected between 1990 and 1995 [40]. For this cohort,
FFPE material was available and tissue cores from each
block were included in a TMA. The TMA blocks in this
cohort are constructed according to histology. Since we
expected a low frequency of ALK rearrangements in
squamous cell carcinoma, we selected TMA blocks of
predominantly adenocarcinoma histology including 143
patients for further analysis.
Information on clinical parameters (age at diagnosis,
sex, smoking history, tumor histology, tumor stage, per-
formance status according to WHO) and overall survival
time was obtained from the records of the population-
based Uppsala-Örebro Regional Lung Cancer Register.
The distribution of clinical parameters (e.g., proportion
of female patients, median age, survival time, etc.) con-
firmed that these cohorts are representative for the oper-
able Swedish NSCLC population [41].
Tissue microarray construction
Tissue microarrays (TMAs) were constructed from
FFPE tumor tissue. All specimens were reviewed by pa-
thologists (Uppsala I and II (JB, HB, PM) and Örebro
(MK)) and representative tumor areas were identified
prior to selecting random cores from the chosen areas
for TMA construction. The Uppsala TMAs were con-
structed using a manual tissue arrayer (MTA-1, Beecher
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Instruments, Sun Prairie, CA). All tumors were included
in duplicates (2 × 1 mm tissue cores). The Örebro TMA
consisted of tumor cores included as triplicates (3 ×
1 mm), as previously described [40].
Fluorescence in situ hybridization (FISH)
ALK rearrangement status was assessed by FISH using
the Vysis ALK Break Apart FISH Probe Kit according to
the manufacturer’s instructions. Four micron thick TMA
sections were used for interphase FISH. Slides were
baked for one hour at 60 °C followed by deparaffiniza-
tion and rehydration. Pretreatment was performed at
80 °C for 20 min followed by protease treatment for
22 min at 37 °C. This was followed by dehydration and
hybridization at 73 °C for three minutes and 37 °C over-
night. Post-hybridization wash was performed at 75 °C
for three minutes and then the slides were mounted with
4′,6-diamidino-2-phenylindole (DAPI) (ProLong® Gold
Antifade Mountant with DAPI, ThermoFisher Scientific).
Slides were analyzed under a x60-x100 oil immersion
objective using an Olympus BX-61 fluorescence micro-
scope (Center Valley, PA) equipped with filters that
visualize the different wavelengths of the fluorescent
probe, a charge-coupled device camera, and the CellA
FISH imaging and capturing software (Olympus Soft Im-
aging Solution GmbH Münster, Germany). A tumor was
considered ALK rearrangement positive if at least 15 %
of 50 (minimum) or 100 analyzed tumor cells showed
split probes signals or isolated orange signals in accord-
ance with published IASLC guidelines (IASLC Atlas of
ALK Testing in Lung Cancer). All FISH experiments
were performed independently (by MAS) without know-
ledge of the IHC results for ALK protein expression.
The discordant cases, which showed FISH positivity but
negative IHC staining, were re-evaluated by both an in-
dependent observer (PM) and by MAS.
Immunohistochemistry
For IHC, four micron thick FFPE sections were mounted
on adhesive slides (SuperFrost Ultra Plus, Thermo Fisher
Scientific, Fermont, CA) followed by incubation for
60 min at 60 °C. The IHC was performed using the same
monoclonal antibody, clone D5F3, with two different
protocols, from here on referred to as the “Ventana
protocol” and the “Dako protocol”. As positive control a
previously diagnosed ALK rearranged NSCLC case was
used, showing strong IHC staining with both protocols.
Automated IHC with the Ventana ALK (D5F3) CDx
Assay (Product no. 790–4796) was performed in a
Benchmark Ultra staining module (Ventana Medical
Systems, Tucson, AZ). In brief, the slides were deparaffi-
nized using EZ prep (Product no. 950–102) followed by
epitope retrieval (Cell conditioner no. 1, pH 8.5, Product
no. 950–124) at 95 °C for eight minutes. After retrieval
the slides were blocked for peroxidase (OptiView perox-
idase inhibitor (included in Product no. 760–700)) for
four minutes. IHC was performed with a monoclonal
rabbit ALK antibody (Ventana, D5F3, RTU) incubated
for 16 min in 36 °C. OptiView DAB IHC Detection Kit
(Product no. 760–700) and OptiView Amplification Kit
(Product no. 760–099) were used according to the man-
ufacturer’s recommendations for visualization of the
bound primary antibody. The slides were then counter-
stained with Hematoxylin II (Product no. 790–2208) for
eight minutes followed by bluing reagent (Product no.
760–2037) for four minutes, prior to dehydration in
graded alcohols.
The Dako protocol was based on an in house protocol
with conditions optimized for the use on a Dako Auto-
stainer. The slides were deparaffinized and pretreated in
Dako PT Link (pre-treatment module) with Target
Retrieval Solution, High pH (K8004, Dako, Glostrup,
Denmark) at 97 °C for 20 min. Endogenous peroxidase
blocking in 0.3 % hydrogen peroxide (5 min) and auto-
mated IHC was then performed on the Autostainer Link
48 (Dako) with the monoclonal rabbit ALK antibody
(Cell Signaling, D5F3, Product no. 3633S) diluted 1:200
in EnVision™ FLEX Antibody Diluent (K8006, Dako) for
20 min at room temperature. Antibody incubation was
followed by standard signal amplification using horse-
radish peroxidase (HRP) conjugated EnVision™ FLEX
(K8000, Dako) at room temperature for 15 min and
developed using 3,3′-diaminobenzidine (DAB) for ten
minutes. The slides were counterstained with Hematoxylin
(Histolab AB, Gothenburg, Sweden, 01820) for eight mi-
nutes and dehydrated in graded alcohols.
Stained slides were mounted with Pertex (Histolab
AB) and scanned using the Aperio ScanScope XT
(Aperio Technologies Inc, Vista, CA) whole slide scan-
ner to generate high-resolution digital images. The
scanned images were viewed in 20× magnification in
the freely available software ImageScope (Aperio Tech-
nologies Inc, Vista, CA), and protein expression was
manually and independently scored by two evaluators
(JM and PM). The intensity of the staining was based
on a four-graded scale: negative (0), weak (1), moderate
(2) and strong (3). The fraction of stained tumor cells
was evaluated as follows: 0 % stained cells (0), 1 % (1),
2–10 % (2), 11–20 % (3), 21–30 % (4), 31–40 % (5), 41–
50 % (6), 51–75 % (7) and > 75 % (8). According to the
Ventana ALK CDx Assay, the samples were classified
as positive if strong (intensity 3) granular cytoplasmic
brown staining was present in any percentage of tumor
cells. Specimens were classified as negative if the tumor
cells displayed no or only weak or moderate cytoplas-
mic staining.
For the Dako protocol, the percentage of stained cells
was taken into account as well. A common annotation
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score was set for the duplicate (Uppsala cohorts) and
triplicate (Örebro) tissue cores representing the same
tumor sample. The ordinal scores for intensity and
fraction of stained tumor cells were then multiplied to
obtain values ranging between 0 and 24. This score was
further dichotomized for the statistical analysis in
negative (score 0–7) and positive protein expression
(score 8–24).
Gene expression microarray
RNA was extracted from frozen tumor tissue from 194
patients operated in Uppsala between 1995 and 2005
and utilized for gene expression microarray analysis on
the Affymetrix HG U133 Plus 2.0 arrays (54675 probe
sets, Affymetrix, Santa Clara, CA), as previously de-
scribed [34, 35]. The Uppsala microarray dataset has
been deposited in the Gene Expression Omnibus (GEO)
data repository (GSE37745), and is openly available [35].
For ALK, two probe sets (208211_s_at; 208212_s_at)
were present on the Affymetrix U133 Plus 2.0 chip set.
Based on the distribution of the gene expression values,
samples were dichotomized into groups with high or
low expression, with a cut-off at 6.
Statistical analysis
The Chi-squared-test was used to determine the per-
formance of the classification. Overall survival (OS) was
calculated from the date of diagnosis to the date of
death. Multivariate Cox survival analysis was performed
with inclusion of established prognostic parameters: age,
patient performance status (not available for Örebro
cohort) and stage at diagnosis. Categorization was per-
formed as follows: age: ≤ 70 vs. > 70 years; performance
status: 0 vs. I–IV, tumor stage: I vs. II–IV. Correlations
between clinical parameters and gene- or protein ex-
pression values were calculated with Spearman’s rank
correlation coefficient. Gene expression was used as a
continuous variable and protein expression was dichot-
omized (high vs. low, as defined in the previous sec-
tion). Adjustment for multiple testing was done by the
Bonferroni–Holm method [42]. All p-values were two-
sided and a statistical significance level of p < 0.05 was
used. All analyses were performed using R version 3.2.3.
Results
Patient characteristics
ALK status was evaluated using TMAs from three inde-
pendent NSCLC patient cohorts (Uppsala I, Uppsala II
and Örebro), comprising in total 851 patients. Clinico-
pathological characteristics for evaluable cases are pro-
vided in Additional file 1: Table S1a-c. The distribution
of clinical parameters did not differ significantly between
Uppsala I and II (all comparisons p > 0.05). The Örebro
cohort was enriched in tumors with adenocarcinoma
histology, compared to Uppsala I and II, but did not dif-
fer significantly with regard to other clinical parameters.
For the subset of Uppsala I patients with available fresh
frozen tissue included in the analysis of gene expression
using Affymetrix microarrays, the distribution of clinico-
pathological parameters were similar to that of the
complete cohort.
ALK status evaluated by fluorescence in-situ hybridization
ALK status using FISH was assessable for 754 (88.6 %)
patients on the TMA. In non-assessable cases, either all
tumor cores were missing on the TMA, the tissue
present on the TMA did not contain any tumor tissue,
or the hybridization was insufficient for reliable evalu-
ation. ALK rearrangement was identified in 13 patients
(1.7 %), including nine adenocarcinomas, two non-small
cell carcinoma not otherwise specified (NOS), and two
squamous cell carcinomas. Both squamous cell carcin-
oma cases were strongly positive for the squamous
marker cytokeratin 5/6 and showed no evidence of ade-
nosquamous differentiation. In the non-squamous cell
carcinoma subgroup, comprising in total 548 patients,
the frequency of ALK positivity was 2.0 % (11 patients).
ALK status evaluated by immunohistochemistry
ALK protein expression was analyzed using automated
IHC on two different platforms (Ventana Benchmark
Ultra and Dako Autostainer Link 48) with two different
protocols.
Using the FDA-approved Ventana ALK (D5F3) CDx
Assay, ALK status was assessable for 791 patients
(92.9 %). ALK positivity, defined according to Ventana
CDx guidelines, was identified in 16 tumors (2.0 %), in-
cluding 12 adenocarcinomas, two non-small cell carcin-
oma NOS, and two squamous cell carcinomas. Of the 16
ALK-positive cases, nine displayed strong homogeneous
positivity in more than 75 % of tumor cells, while strong
staining in 1–40 % of tumor cells was observed in the
remaining seven tumors.
Using the same anti-ALK antibody clone ordered sep-
arately (Cell Signaling) together with an existing in
house Dako protocol, ALK status was assessable for
806 patients (94.7 %). ALK positivity, defined based on
an immunoreactivity score that takes both the intensity
and the fraction of positive tumor cells into account,
was identified in 12 tumors (1.5 %), including 11 adeno-
carcinomas and one non-small cell carcinoma NOS. Of
the 12 ALK-positive tumors, three showed strong
homogeneous staining in more than 75 % of the tumor
cells, while lower immunoreactivity scores and a vary-
ing pattern with regard to staining intensity and frac-
tion of positive tumor cells was observed for the
remaining nine tumors.
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Re-evaluation of TMA results on whole tissue sections
Although TMAs are excellent for screening, the selected
tumor cores from each case do not necessarily represent
the whole tumor and thus results may be influenced by
intratumoral heterogeneity, a scenario that mimics small
diagnostic biopsies in the clinical setting. To address this
potential issue, all tumors that showed ALK-positivity in
at least one assay, or a contradicting result in one or two
other assays (24 tumors), were re-evaluated on a corre-
sponding whole tissue section using all three assays
(FISH and the two IHC protocols). All cases interpreted
as FISH positive on the TMA were also annotated as
positive in the FISH analysis on whole tissue section.
The re-evaluation of the Ventana IHC analysis led to the
re-annotation of two cases from positive to negative
(303 and L694) (Fig. 1a and b). The re-evaluation of the
Dako IHC analysis resulted in the re-classification of
two cases from positive to negative (223 and L826) and
one case from negative to positive (L694) (Fig. 1b-d). For
these five cases we used the results based on the whole
tissue sections in the further analysis. Final results and
percentages after re-evaluation are seen in Table 1.
After re-evaluation on whole tissue section, the num-
ber of FISH positive cases remained unchanged (1.7 %).
The number of positive cases declined to 14 (1.8 %)
cases and to 11 (1.4 %) cases with the Ventana assay and
the Dako assay, respectively.
Comparison between the two immunohistochemical
protocols
First, we wanted to evaluate the agreement between the
two IHC assays (both using anti-ALK clone D5F3), a
comparison which is important as the Ventana CDx
Assay recently received FDA-approval to replace FISH
analysis for the selection of patients eligible for ALK in-
hibitor treatment and is likely to replace existing in
house validated protocol.
Altogether 789 cases were evaluable for both IHC as-
says. Of 15 cases that were positive in at least one of the
IHC assays, only ten (66.7 %) were positive with both
protocols (Fig. 2a). The Ventana protocol defined four
cases as positive (strong staining in 1–50 % of the cancer
cells) but these were annotated as negative with the
Dako protocol (weak to moderate staining in 1–30 % of
the cells, below our defined cut-off ). One of the four
cases annotated as positive with the Ventana protocol
was of squamous cell histology (Fig. 3a-d). The Dako
protocol defined one additional case as positive, with
strong staining in 31–40 % of tumor cells (Fig. 3e). This
case was completely negative with the Ventana protocol.
Thus, the ‘retrospectively screening’ for ALK inhibitor
therapy eligibility, using the Ventana CDx Assay instead
of our in house protocol, led to the identification of four
additional patients who else would not have been further
considered for targeted treatment.
Comparison between FISH and IHC Ventana CDx protocol
The concordance between ALK status determined by
FISH and IHC is of high importance, when IHC is sug-
gested to replace FISH for identification of the patient
subset likely to benefit from ALK inhibitor therapy.
In our study, 712 tumors could be evaluated with both
FISH and IHC using the Ventana CDx Assay. Of 13
FISH positive tumors, nine were found to be positive ac-
cording to the Ventana CDx Assay (Fig. 2b). These nine
concordant cases showed strong protein expression in
21–100 % of the tumor cells. Additionally, four cases
were rearranged according to FISH but did not display
positivity on the protein level (Fig. 4a). Furthermore, five
tumors were ALK positive according to the Ventana
CDx Assay, but were not found to be rearranged using
FISH (Fig. 4b). These five cases displayed strong staining
in between 1 and 30 % of the cells. Considering FISH as
the reference method, the sensitivity of the Ventana CDx
Assay was 69.2 % with a specificity of 99.3 % and an
accuracy of 99 % (Fig. 2b).
Comparison between FISH and IHC Dako protocol
Next, we assessed the overlap between FISH and IHC
positive tumors using the Dako IHC-protocol. The num-
ber of assessable tumors evaluated with both assays was
726. Of the 13 FISH positive tumors, eight were also
positive according to the Dako protocol (Fig. 2c). Six of
these eight concordant cases showed strong positive pro-
tein expression ranging between 50 and 100 % in the
cells (scores ranging between 15 and 24), and two cases
displayed weak staining in > 75 % of the cells (score 8).
Additionally, five cases were rearranged according to
FISH analysis, but these cases showed negative protein
expression (Fig. 4a). Furthermore, according to the IHC
analysis, three additional cases displayed positive protein
expression when using the Dako protocol but were FISH
negative (Fig. 4b). Considering FISH as the reference
method the sensitivity of the in house IHC assay was
61.5 % with a specificity of 99.6 % and an accuracy of
98.9 % (Fig. 2c).
The results of the comparisons between FISH and
both IHC assays are illustrated in Fig. 5.
Gene expression microarray
Today, it is unclear if genomic rearrangement leading to
the expression of the ALK fusion gene is the sole pre-
dictor of response to ALK inhibitor therapy or if patients
that show high ALK levels, regardless of the underlying
cause, are equally receptive to therapeutic ALK inhib-
ition. To evaluate the pattern of high ALK expression
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we compared mRNA levels to protein expression and
FISH status in a subset of patients.
Fresh frozen tissue of 194 cases from the Uppsala I co-
hort (54.8 %) were analyzed by Affymetrix gene expres-
sion microarray for ALK gene expression represented by
two probe sets. With the probe set 208211_s_at, two
cases (1.0 %) were positive (gene expression values of
≥ 6), while with probe set 208212_s_at, six cases (3.1 %)
were positive, with an overlap of two cases with probe
set 208211_s_at. Thus, six cases were defined as gene ex-
pression positive (Fig. 6). Only three of the six cases
were positive according to one of the three other ALK
assays (FISH, Ventana and Dako IHC) (Fig. 2d). Import-
antly, the two cases with the highest gene expression
303 TMA
Dako 0x0 = negative 
L694 TMA
Ventana 3x2 = positive 
b)
L694 TMA







Ventana 3x1 = positive 
a)
223 TMA 
Ventana 3x8 = positive 
c)
223 TMA 
Dako 2x6 = positive 
303 Whole section
Ventana 0x0 = negative 
L694 Whole section
Dako 3x5 = positive
303 Whole section
Dako 0x0 = negative 
L694 Whole section
Ventana 0x0 = negative
223 Whole section
Dako1x3 = negative 
223 Whole section
Ventana 3x6 = positive 
L826 Whole section
Ventana 0x0=negative
L826 Whole section 
Dako 3x2=negative
Fig. 1 Re-evaluation of the discordant cases: a 303: Using the Ventana IHC protocol the staining of the tissue core was annotated as positive
(strong staining in 1 % of the tumors cells). The corresponding whole section did not show any protein expression. The Dako protocol was
negative on both the TMA and the whole section. The FISH analysis was also negative. b L694: Using the Ventana IHC protocol the staining of
the tissue core was annotated as positive (strong staining in 2–10 % of tumors cells). The corresponding whole section did not show any protein
expression. The Dako protocol resulted in an opposite assessment with a negative result on the TMA and a positive result on the whole section.
The FISH analysis was negative for this case. c 223: This case was annotated as positive with the Dako protocol on the TMA (moderate staining in
41–50 % of tumor cells) but was scored negative when the whole section was evaluated. This case was defined as positive both with Ventana
IHC assay and the FISH assay. d L826: This case was annotated as positive with the in house Dako protocol on the TMA (strong staining in 41–
50 % of tumor cells) but was scored negative when the whole section was evaluated. The Ventana IHC assay and the FISH analysis were negative
on the TMA as well as on the whole sections. The scale bar in all images represents 100 μm
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(gene expression values 8.2 and 7) values were also FISH
positive. Three of the six cases were of the adenocarcin-
oma histology, one was NSCLC NOS, while the two
remaining cases were squamous cell carcinomas.
Correlation to clinical parameters
Clinical parameters, including survival, were available
for all three cohorts as listed in Additional file 1: Table
S1. As expected, the correlation analysis revealed that
ALK positivity was associated with lower age, female
sex, and non-smoking (Table 2), but the grade of associ-
ation was variable depending on the assay used, with sig-
nificant association only for smoking status and gender.
The ALK positive samples with the Dako protocol
showed the strongest associations to age (p = 0.11), gen-
der (p = 0.03) and smoking status (p < 0.001), while ALK
positivity in the Ventana assay and in the FISH assay
demonstrated clearly weaker associations except for
smoking (p < 0.001).
A Cox regression model was applied to test the associ-
ation of ALK status with survival combining all three co-
horts. A weak tendency towards a better overall survival
for ALK positive patients was seen with all three assays
when all histologies were analyzed together (p = 0.26–
0.37, all analyses, Table 3).
Discussion
In this study we evaluated the frequency of ALK rear-
rangements as well as the relation between ALK fusion,
protein expression and gene expression in three repre-
sentative Swedish NSCLC cohorts. We found that the
incidence of ALK fusions in our NSCLC population is
Table 1 Results of all cases with ALK positivity in at least one of the assays. All cases that demonstrated positivity in one of the
assays (Ventana protocol, Dako protocol, FISH analysis or Affymetrix gene expression microarray) were re-analyzed on whole tissue
sections and the results are given in the table. Defined positivity is indicated by green color. Included in the table are also information
about the age of the sample (years), histology and smoking
Histology: AC=adenocarcinoma, SqCC=squamous cell carcinoma, NOS=not otherwise specified
Sample Ventana Dako Affymetrix
ID age Histology Smoking Intensity Quantity Score Intensity Quantity Score FISH 208212_s_at
L473 8 AC Current 3 1 3 2 4 8 neg -
L608T2 6 SqCC Ex 3 3 9 1 2 2 neg -
L670 6 AC Never 3 8 24 3 8 24 pos -
L679 6 AC Never 3 8 24 3 8 24 pos -
L694 6 AC Current 0 0 0 3 5 15 neg -
L700 6 SqCC Current 0 0 0 0 0 0 pos -
L743 5 AC Never 3 8 24 3 8 24 pos -
L773 5 AC Ex 3 8 24 3 8 24 pos -
L826 6 AC Never 0 0 0 3 2 6 neg -
L828 6 AC Never 3 4 12 1 8 8 pos -
L834T1 6 NOS Ex 3 1 3 0 0 0 neg -
L863 6 NOS Never 0 0 0 0 0 0 pos -
40 13 SqCC Ex 0 0 0 1 1 1 pos -
130 10 SqCC Ex 0 0 0 0 0 0 neg 6.7
182 18 NOS Ex 2 1 2 0 0 0 neg 6.0
210 16 AC Never 3 8 24 3 7 21 pos -
223 15 AC Ex 3 6 18 1 3 3 pos 8.2
260 13 AC Ex 3 3 9 2 2 4 neg 6.4
284 18 AC Ex 3 8 24 3 7 21 pos 7.5
303 17 SqCC Current 0 0 0 0 0 0 neg -
370 19 SqCC Ex 1 1 1 0 0 0 neg 6.2
Ö68 22 AC Current/Ex 0 0 0 0 0 0 pos -
Ö82 21 AC Current/Ex 3 4 12 3 4 12 neg -
Ö129 25 NOS Never 3 5 15 1 8 8 pos -
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lower than previously reported, independent of the assay
used. Also, in contrast to previous studies [43–46], the
different assays did not show convincing concordance,
indicating that they are not interchangeable. Thus, in
the clinical setting they should be used with caution.
Notably, using FISH we found ALK rearrangements in
squamous cell carcinomas (2 of 13 cases, 15 %), a clin-
ically relevant finding that deserves specific attention,
as 15 % of positive cases would not have been identified
if the analysis had been focused on non-squamous can-
cers only.
Previous reports mostly demonstrated ALK rearrange-
ment frequencies of 3-5 % in unselected patient popula-
tions [47–49], 3–25 % in adenocarcinomas [50–53], and
33 % in highly selected patient populations (EGFR wild-
type, female, non/light smokers) [8]. Our frequency is
lower, with 1.7 % FISH positive cases, and 2.0 % positive
cases in non-squamous patients. Several factors might
have influenced this result: (1) this study is performed
on a Swedish population and maybe these patients are
less prone to develop ALK fusion genes. One other study
from Finland [54] evaluated 87 NSCLC patients enriched
for non-smokers and adenocarcinomas, and displayed an
ALK fusion frequency of 5.7 %, which would also be
considered as comparably low for selected patients. (2)
The frequency of ALK fusion in resected, hence localized
tumors, is maybe lower than in advanced patients that
were mostly analyzed in other studies. Indeed, one large
study of resected adenocarcinoma patients, revealed a
frequency of only 2.2 % FISH positive cases [28], thus
only slightly higher than in in our study. (3) Based on
these arguments, we believe that the frequency of
around 2 % reflects the real clinical scenario in this un-
selected Swedish population of localized NSCLC.
A clinically relevant finding is the imperfect overlap of
IHC and FISH. The sensitivity of the Ventana protocol
and the Dako protocol was only 69.2 and 61.5 %, re-
spectively, when FISH results were considered as the
gold standard. Although, the specificity was high, 99.3
and 99.6 % respectively, the performance of the assays,
detecting around two thirds of positive cases, might be
regarded as insufficient. The low sensitivity witnessed in
this study was in contrast to other studies demonstrating
higher sensitivities ranging between 90 and 100 % for
the antibody clone D5F3 [45, 55–63], suggesting that
IHC as a screening method may be a complement to, or
completely replace ALK-FISH [30, 31, 64]. A problem
in several of these studies is that tissue specimens
were screened with IHC and later confirmed with
FISH providing an excellent but misleading high sensi-
tivity [28, 65–67]. Indeed, there are recent studies
comparing FISH and IHC techniques with sensitivities
below 90 % [47, 68–70]. Also the analysis of the two
clinical phase III studies 1014 and 1029 leading to the
FDA approval of the Ventana ALK (D5F3) CDx Assay
demonstrated a sensitivity of 86 and 93 %, respect-
ively, i.e., leading to the exclusion of 14 % patients
from a highly effective therapy option in study 1014
IHC DakoFISH
n=726











Fig. 2 Venn diagram of ALK positivity based on different analyses. a Immunohistochemical positivity was compared between the Ventana IHC
and Dako protocol. b Samples with positive FISH were compared to samples with positive Ventana protein expression. c Samples with positive
FISH were compared to samples with positive protein expression when using the Dako protocol. d Samples with positive FISH, Ventana IHC, in
house Dako IHC or Affymetrix gene expression were compared to each other
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([71], NCT01639001). These results should be consid-
ered when institutions incorporate ALK-IHC as an ini-
tial screening method prior to FISH testing, a strategy
that is already discussed in most of the current
guidelines.
The comparison of our previously used in house Dako
IHC protocol with the FDA approved Ventana assay re-
vealed a surprising discordance, although both protocols
use the same antibody clone D5F3. Some of the incon-
sistencies may be explained by analytical factors such as
different staining instruments and different secondary
signal amplifications methods. Moreover, we used a dif-
ferent cut-off defining positivity for the in house assay.
Our study indicates a higher sensitivity when using the
Ventana system compared to the in house protocol
(69 % vs. 62 %). Together with the FDA approved
standardization and the straight forward annotation of
positivity, the use of the Ventana protocol will be more
appropriate in the diagnostic setting.
Another question that emerged, considering the sur-
prisingly high discrepancy between IHC and FISH, is if
FISH should be regarded as the gold standard in the
clinical setting? Although FISH has many favorable fea-
tures, for instance being able to detect ALK rearrange-
ments regardless of fusion partner, several arguments
contrast this assumption: FISH evaluation is dependent
on many pre-analytical factors, such as fixation time
and what type of fixative used. Another factor affect-
ing the result is the storage condition of the blocks
and the cut sections. Analytical factors such as the
hybridization process, although standardized for most
protocol, may not work optimally for every sample,
since it is dependent on how the tissue is composed
[72]. Also, the read out with a split event in a small
part of the short arm of chromosome 2 is difficult to
be surely detectable and the cut off of 15 % of split
positive cells is maybe not optimal. Thus, the inter-
pretation of ALK status in the routine settings pre-
sents the highest challenge in diagnostics, in particular
on small biopsy cores and when the hybridization of
the probes is suboptimal. With this background it
would be reasonable in clinical diagnostics to test with
Dako IHC 1x2=negVentana IHC 3x3=pos
Ventana IHC 3x6=pos Dako IHC 1x3=neg Ventana IHC 3x3=pos Dako IHC 2x2=neg
a) Sample 223: FISH positive b) Sample 260: FISH negative
Dako IHC 3x5=posVentana IHC  0x0=neg
Dako IHC 0x0=negVentana IHC 3x1=pos
c) Sample L608T2: FISH negative d) Sample L834T1: FISH negative
e) Sample L694: FISH negative
Fig. 3 Discordant cases with the immunohistochemical assays: a 223: The case was defined as positive with the Ventana protocol but did not
show relevant staining with the Dako protocol. The corresponding FISH analysis indicated an ALK rearrangement (cores and whole section). b
260: This case revealed a positive staining with the Ventana assay but was not positive according the defined cut-off of the in house Dako assay.
In this case the FISH analysis did not demonstrate a rearrangement. c L608T2: This case demonstrated a positive staining with the Ventana
assay, but was negative according to the Dako assay. This case was negative with FISH. d 2L834T1: This sample was positive with the Ventana
assay, but negative with the Dako assay. The FISH analysis did not show a rearrangement. e L694: This case was negative according to the Ventana
staining, but positive according to the Dako assay. FISH did not demonstrate a rearrangement. The scale bar in all images represents 100 μm















Fig. 4 Discordant case between FISH and immunohistochemical Ventana assay: a L700: The FISH assay indicated an ALK fusion gene, but
immunohistochemical staining using the Ventana protocol demonstrated no relevant protein expression. b Ö82: This case was negative with
the FISH assay, but showed a clear positive staining with the Ventana and the in house assay. The scale bar in the FISH and IHC images
represents 10 and 100 μm, respectively
Ventana ALK (D5F3) CDx Assay vs. Dako IHC protocol vs. FISH
































































IHC-Ventana: Ventana ALK (D5F3) CDx Assay
IHC-Dako: In-house IHC protocol (Cell Signaling ALK (D5F3®) XP® Rabbit mAb)



























Number of cases (n): 8 1 4 1 2 0 3 691
Fig. 5 Comparisons between the FISH assay and the both IHC assays. Summary of the cases from the three cohorts available for ALK evaluation
with FISH, the Ventana assay and the Dako assay
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IHC and FISH in parallel. A more pragmatic alterna-
tive would be to screen with IHC and to test all
patients with a higher probability (non-smokers, youn-
ger age) of ALK rearrangements with FISH. It should
be stressed that also histological features, as the re-
cently described mucinous-cribriform/papillary histo-
logic growth pattern, are strongly correlated with the
presence of fusion genes [73, 74] and thus can be used
as a criteria for ALK-testing.
To circumvent these problems, other techniques have
been introduced to detect ALK rearrangement in the diag-
nostic setting. The group of Nitta et al. developed a IHC
detection system with increased sensitivity that is used in
combination with a bright field in situ hybridization assay,
providing a co-visualization of protein expression and
genomic ALK rearrangement [75].
Other alternatives for ALK fusion gene detection in-
cludes RT-PCR based assays [76], but these techniques are
relying on the knowledge of the fusion transcript variants
probably resulting in false negative cases. Recently, next
generation sequencing methods have been developed, like
RNA sequencing, to catch hitherto unknown fusion genes
[77]. The nCounter system (NanoString Technologies, Se-
attle, WA) presents a new promising method to quantify
RNA without using RT-PCR. Multiple RNA molecules
were directly quantified after simultaneous hybridization
[78]. For ALK analysis NanoString uses a multiplex com-
bination of ALK fusion transcripts detection and deter-
mination of an ALK 3′ transcript overexpression. This is a
relatively inexpensive and fast technique that has showed
highly concordant results with FISH and IHC [79]. Fur-
thermore, the simultaneous detection of other NSCLC fu-
sion genes (RET, ROS1, NRG1, and BRAF) and the MET
skipping transcript is possible [80]. We believe that this
technology will replace both FISH and IHC analyses in
the future diagnostic algorithms.
Based on the notion that protein expression corre-


















Fig. 6 Gene expression of ALK using microarray analysis. Affymetrix gene expression data of probe set 208212_s_at from 194 NSCLC cases from
the Uppsala cohort I. Relative gene expression signals are given as log-values. Samples with positivity in one of the FISH or IHC assays are
designated in the magnification. All other cases with available gene expression data were negative
Table 2 Correlations between clinical parameters and the three ALK rearrangement detection methods in all three cohorts
FISH Ventana IHC Dako IHC
Variable Correlation P-value Correlation P-value Correlation P-value
Gender 0.020 0.601 0.043 0.230 0.078 0.028
Age −0.002 0.959 −0.049 0.167 −0.057 0.108
Stage 0.047 0.197 0.035 0.326 0.042 0.238
Smoking −0.188 <0.001 −0.140 <0.001 −0.166 <0.001
FISH positive vs negative, Ventana IHC Assay intensity 3 vs the other intensities, Dako IHC Assay score <8 vs. ≥8, Age at diagnosis ≤70 years vs. >70 years, Stage IA
+ IB vs. II-IV, Smoking smokers + ex-smokers vs. never smokers
Mattsson et al. BMC Cancer  (2016) 16:603 Page 11 of 15
expression levels are associated with the ALK status.
We found that the two cases with the highest gene
expression demonstrated FISH and IHC positivity. Al-
though higher gene expression of the 3′ end of ALK
has been used as one criterion in recently presented de-
tection methods [79], the significance of a general
higher ALK expression without fusion has not been
evaluated. It is to speculate, if the four FISH negative
cases with high gene expression observed in our study
present a subgroup of patients that may also benefit
from ALK inhibitor therapy. The same situation could
refer to FISH negative cases with high protein expres-
sion, in our study altogether six patients. Indeed, there
are several case studies reporting objective responses to
crizotinib therapy in FISH negative cases [49, 81, 82].
The major strength of our study is the unbiased strat-
egy to perform all analysis independently and in parallel
in this large NSCLC population. Indeed, with more than
700 patients, our study presents one of the largest sys-
tematic analyses of ALK status in NSCLC patients. The
use of TMAs could be considered as a disadvantage;
however, from the clinical perspective the TMA with
small tissue cores reflects the small sample size of biop-
sies tested in routine diagnostics. While none of the
FISH results changed when compared to the analysis of
the corresponding whole section, the IHC on whole sec-
tion led to re-annotation of two of 24 cases for the Ven-
tana assay and three of 24 of the in house assay. This
difference most likely indicates tissue heterogeneity of
protein expression, leading to the described uncertainty
of IHC in small biopsies. Naturally, a comparative ana-
lysis of TMA cores and whole section would be of inter-
est, but was beyond the scope of this study.
Conclusions
The results of our large comparative study indicate a
low frequency of ALK aberrations in the Swedish popu-
lation of NSCLC patients. Although we tested a FDA ap-
proved IHC assay to detect ALK protein expression, the
sensitivity is relatively low, thus questioning its suitabil-
ity for use as a screening assay. The discordant results
also stress the need for careful validation of all ALK de-
tection methods before they can be implemented into
clinical practice. Finally, we demonstrated that there are
patients with high ALK protein and mRNA levels that
do not harbor ALK rearrangement according to FISH,
maybe indicating a distinct group of patients that would
also benefit from ALK inhibition.
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